Withania somnifera as a safer option to hydroxychloroquine in the chemoprophylaxis of COVID-19: Results of interim analysis
Chopra A, Srikanth N, Patwardhan B, AYUSH CCRAS Research Group
Complementary therapies in medicine · 15 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Ministry of AYUSH, Government of India
- Gobierno
- Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy
Según 2 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2021-08-18 · Complement Ther Med · vol. 62 · pág. 102768
- Editorial
- Elsevier BV
- Citado
- 28 citas · más que el 97% de estudios similares · 6.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 8 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC-ND
- Áreas de investigación
- Phytochemicals and Medicinal Plants · Andrographolide Research and Applications · Diverse Scientific Research Studies
- Palabras clave
- Medicine, Withania somnifera, Hydroxychloroquine, Interim analysis, Randomized controlled trial, Chemoprophylaxis, Placebo, Internal medicine, Coronavirus disease 2019 (COVID-19), Alternative medicine, Pathology
- MeSH
- humans, withania, hydroxychloroquine, treatment outcome, prospective studies, adult, middle aged, female, male, covid-19
3 autores
- Arvind Chopra🇯🇵Institute for Rheumatic Diseases (Japan)
- Narayanam Srikanth🇮🇳Central Council for Research in Ayurvedic Science
- Bhushan Patwardhan🇮🇳 · autor de correspondenciaSavitribai Phule Pune University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
To study the efficacy and safety of Withania somnifera (WS, Ashwagandha) in the prophylaxis against COVID-19 in high risk health care workers (HCW) in comparison to hydroxychloroquine (HCQ). To evaluate the general physical and mental health benefits of Ashwagandha.
Methods
A 16 week randomized prospective, open-label, parallel efficacy, two arm, multi-centre study. The primary efficacy measure was 'failure of prophylaxis' as confirmed COVID-19 by quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) at any time during the study period. This study on 400 participants from three centres was designed to establish non-inferiority for WS to HCQ for prophylaxis against COVID-19 at 80 % power and significance p < 0.025, one-sided. The interim analysis was carried out on 160 participants after completion of 8 weeks.
Results
Participants in both the arms were well-matched at the baseline characteristics. Forty participants in the HCQ group and 26 participants in the WS group reported mild AE. The symptoms of confirmed COVID-19 were found to be 3.7 % (95 % CI 1.3-10.5 %) in the HCQ and 1.3 % (95 % CI 0.02-6.7 %) in the WS arm amongst the first 160 participants completing 8 weeks.
Conclusion
Our intent was to explore a safer option to HCQ. We report that WS was not found inferior to HCQ and its efficacy was within the 15 % non-inferiority margin set a priori. WS as an immunomodulator has other clinical benefits including reducing mental stress. The final report of this study is expected by end of August 2021.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.